Incyte Corporation (BVMF:I1NC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 104.14B +48.4% |
| Revenue (ttm) | 27.97B +21.5% |
| Net Income | 7.47B +6,631.4% |
| EPS | 36.82 +7,175.4% |
| Shares Out | n/a |
| PE Ratio | 13.94 |
| Forward PE | 13.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14 |
| Open | 239.28 |
| Previous Close | 244.00 |
| Day's Range | 237.84 - 239.28 |
| 52-Week Range | 185.15 - 299.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy to diversify revenue streams, accelerate pipeline assets, and drive growth through business development and targeted launches. Key programs in hematology and immunology are advancing, with several pivotal trials and major data readouts expected by 2027.
Incyte price target raised to $107 from $90 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Incyte (INCY) to $107 from $90 and keeps a Perform rating on the shares after the company announced the acquisition…
Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal
After Incyte (INCY) announced it has entered into an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B, Jefferies analyst Maury Raycroft said the deal…
Incyte Transcript: M&A announcement
Acquisition of a phase III-ready asset in von Willebrand disease strengthens the hematology portfolio, with $1.25B upfront and $750M in milestones. VGA039 offers a differentiated, once-monthly therapy with blockbuster potential and strong regulatory alignment.
Incyte Press release: M&A announcement
Incyte issued a press release on June 8, 2026, disclosing material business information to investors.
Incyte Slides: M&A announcement
Incyte has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disor...
Incyte to acquire Vega Therapeutics for $1.25B
Incyte (INCY) announced it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to recei...
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders.
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the m...
Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossif...
Incyte announces results from Phase 3 frontMIND trial on tafasitamab
Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and l...
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death...
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.
Incyte Proxy statement: Proxy filing
Incyte filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference.
Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound
Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target The firm is concerned that there is no clear pathway for revenue growth to return…
Incyte initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target
Inside Incyte's $120 Million AI For Drug Development Deal
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.
Incyte, Genesis Molecular AI announce expansion of collaboration
Incyte (INCY) and Genesis Molecular AI announced a significant expansion of their strategic collaboration building and deploying AI to accelerate the discovery of novel molecules for collaboration tar...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery.
Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026
Phase III for mutant CALR antibody 989 in ET starts mid-year with a novel, user-friendly design and rapid endpoints. MF program pursues composite endpoints, while subQ formulations and next-gen assets advance. Jakafi XR, tafasitamab, and povo are positioned for significant market growth.
Incyte, Edison Scientific announce strategic collaboration to employ Kosmos
Incyte (INCY) and Edison Scientific announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. Kosmos will be embedded across the Incyte ...
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
WILMINGTON, Del. & SAN FRANCISCO--(BUSINESS WIRE)---- $INCY--Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development.